The optimum dosage level is interesting.
When tested in a 28-day Fragile-X knockout mouse model, NNZ-2591 demonstrated similar normalizing impact on behaviours.
However, the dosage administered in that study was 30 mg/kg, whereas these 6-week results in Phelan McDermid syndrome were achieved with an optimum dose of just 4 mg/kg.
http://www.neurenpharma.com/irm/PDF/1635_0/Posterat2013FRAXAInvestigatorsMeeting
Ann: Compelling results for 2591 dose ranging study in PMS model, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.81 |
Change
-0.155(1.20%) |
Mkt cap ! $1.609B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.70 | $2.892M | 224.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 260 | $12.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.81 | 191 | 2 |
View Market Depth
| Last trade - 14.17pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |